In:
Alzheimer's & Dementia, Wiley, Vol. 15, No. 9 ( 2019-09), p. 1133-1148
Abstract:
Immunotherapeutic approaches targeting amyloid β (Aβ) protein and tau in Alzheimer's disease and α‐synuclein (α‐syn) in Parkinson's disease are being developed for treating dementia with Lewy bodies. However, it is unknown if single or combined immunotherapies targeting Aβ and/or α‐syn may be effective. Methods Amyloid precursor protein/α‐syn tg mice were immunized with AFFITOPEs® (AFF) peptides specific to Aβ (AD02) or α‐syn (PD‐AFF1) and the combination. Results AD02 more effectively reduced Aβ and pTau burden; however, the combination exhibited some additive effects. Both AD02 and PD‐AFF1 effectively reduced α‐syn, ameliorated degeneration of pyramidal neurons, and reduced neuroinflammation. PD‐AFF1 more effectively ameliorated cholinergic and dopaminergic fiber loss; the combined immunization displayed additive effects. AD02 more effectively improved buried pellet test behavior, whereas PD‐AFF1 more effectively improved horizontal beam test; the combined immunization displayed additive effects. Discussion Specific active immunotherapy targeting Aβ and/or α‐syn may be of potential interest for the treatment of dementia with Lewy bodies.
Type of Medium:
Online Resource
ISSN:
1552-5260
,
1552-5279
DOI:
10.1016/j.jalz.2019.02.002
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2201940-6
Bookmarklink